Adems, al menos en Brasil, el medicamento slo est autorizado para el tratamiento de la diabetes tipo 2
even though social media is not necessarily representative, a large collection of posts may reflect additional concerns. The researchers caution that their findings are not causal
GLP-1 exposure cases include calls made by people with a suspected poisoning or by people who are experiencing any side effect or symptom after taking the wrong dosage of a medication, or even when they are taking it as prescribed
No interference
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits (review)
Frankly, in routine clinical practice, optimal care just doesn't happen as consistently. If we're right, and these therapies are effective, you have at least a 50% chance of getting that treatment long before it's approved for use in type 1 diabetes